Project Grant R03HL172985
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$131K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $692,768 in funding to Rhode Island Hospital, a division of Lifespan Corporation, from March 1, 2025 through December 31, 2028. The grant supports research to define endothelial cell dysfunction in pulmonary arterial hypertension (PAH) and identify factors that influence endophenotypes. The central hypothesis is that anoikis...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $242,310 Project Grant to the University of Pittsburgh - Of The Commonwealth System of Higher Education to fund research aimed at investigating the role of NADPH oxidase 1 (NOX1) and AMP-activated protein kinase alpha-1 (AMPKA1) in the pathogenesis of pulmonary arterial hypertension (PAH). The research project, which runs from June 2024 to January 2026, seeks to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $167,940 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a new mouse model of flow-induced pulmonary hypertension (PH) that better represents the physiological conditions of patients with congenital heart disease (CHD). The project aims to gain key insights into the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to better understand changes in the pulmonary vasculature and their relationship to lung disease in patients with pulmonary hypertension and chronic obstructive pulmonary disease (COPD). The $812,189 award, effective May 1, 2025 through February 28, 2029, will leverage data from several NIH-funded cohorts, including...
The federal Project Grant award R01HL174472, totaling $1,535,625.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant supports research on ZFP36, an RNA-binding protein that regulates DNA repair and cell proliferation in pulmonary arterial hypertension (PAH). The research conducted at the University of California, Los Angeles (UCLA) aims to decode the causes of gene expression deregulation in PAH and...
This $764,891 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research at Baylor College of Medicine to define new regulatory mechanisms governing vascular remodeling in pulmonary hypertension associated with interstitial lung disease (ILD-PH). The primary objectives are to: Characterize the transcriptional regulation of the BMPER gene, which encodes a secreted protein that regulates vascular development, during...
The federal Project Grant award "IDENTIFYING CLINICAL MARKERS OF RIGHT VENTRICULAR ADAPTATION TO IMPROVE SURVIVAL PREDICTIONS IN PULMONARY ARTERIAL HYPERTENSION" is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for $102,932. The grant supports research to identify clinically accessible metrics that can serve as surrogates for right ventricular-pulmonary arterial (RV-PA) coupling, a key indicator of right...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $658,885 to the University of Missouri System to conduct research on targeting the Response Gene to Complement 32 (RGC-32) to alleviate vascular remodeling in pulmonary arterial hypertension (PAH). The key objectives are to determine the molecular mechanisms by which RGC-32 regulates the endothelial-mesenchymal transition (EnDoMT)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $162,540 to The Trustees of the University of Pennsylvania for a 2-year research project starting on September 1, 2024. The project aims to investigate the impact of aging on mitochondrial quality control, metabolic disruption, and alveolar epithelial type 2 (AT2) progenitor cell function in pulmonary fibrosis. The research...